Literature DB >> 10209234

The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas.

M Bredel1, I F Pollack.   

Abstract

Deregulated p21-Ras function, as a result of mutation, overexpression or growth factor-induced overactivation, contributes to at least 30% of human cancer. This article reviews the potential role of the p21-Ras family of GTPases in the regulation of growth of high-grade gliomas and describes how targeting this oncoprotein clinically may provide a novel strategy to counteract glioma proliferation. The application of strategies directed at selectively opposing the deregulated signal transduction pathway of high-grade gliomas may be of potential therapeutic benefit and may offer a whole new arsenal of antineoplastic agents to be included in the multimodal treatment of these challenging neoplasms. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10209234     DOI: 10.1016/s0165-0173(98)00057-5

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  10 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620.

Authors:  Masanori Kurimoto; Yutaka Hirashima; Hideo Hamada; Hironaga Kamiyama; Shoichi Nagai; Nakamasa Hayashi; Shunro Endo
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 3.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  CArG binding factor A (CBF-A) is involved in transcriptional regulation of the rat Ha-ras promoter.

Authors:  A M Mikheev; S A Mikheev; Y Zhang; R Aebersold; H Zarbl
Journal:  Nucleic Acids Res       Date:  2000-10-01       Impact factor: 16.971

5.  Fuzzy rules to predict degree of malignancy in brain glioma.

Authors:  C Z Ye; J Yang; D Y Geng; Y Zhou; N Y Chen
Journal:  Med Biol Eng Comput       Date:  2002-03       Impact factor: 2.602

6.  The role of ecto-5'-nucleotidase/CD73 in glioma cell line proliferation.

Authors:  Luci Bavaresco; Andressa Bernardi; Elizandra Braganhol; Angélica Regina Cappellari; Liliana Rockenbach; Patrícia Fernandes Farias; Márcia Rosângela Wink; Andrés Delgado-Cañedo; Ana Maria Oliveira Battastini
Journal:  Mol Cell Biochem       Date:  2008-07-18       Impact factor: 3.396

7.  Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.

Authors:  Ersoy Oksuz; Fatmahan Atalar; Gamze Tanırverdi; Ayahan Bilir; Andleeb Shahzadi; Zeliha Yazici
Journal:  J Neurooncol       Date:  2015-10-27       Impact factor: 4.130

Review 8.  Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.

Authors:  Fabliha Ahmed Chowdhury; Md Kamal Hossain; A G M Mostofa; Maruf Mohammad Akbor; Muhammad Shahdaat Bin Sayeed
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

9.  Aberrant signaling pathways in glioma.

Authors:  Mitsutoshi Nakada; Daisuke Kita; Takuya Watanabe; Yutaka Hayashi; Lei Teng; Ilya V Pyko; Jun-Ichiro Hamada
Journal:  Cancers (Basel)       Date:  2011-08-10       Impact factor: 6.639

10.  Metallic nickel nanoparticles may exhibit higher carcinogenic potential than fine particles in JB6 cells.

Authors:  Ruth Magaye; Qi Zhou; Linda Bowman; Baobo Zou; Guochuan Mao; Jin Xu; Vincent Castranova; Jinshun Zhao; Min Ding
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.